5-Bromo-6-chloropyrazin-2-amine

Art. -Nr.: HY-W003686 Reinheit: 99.79%: Data Sheet
COA

SDS
Handling Instructions
FAQs
Technical Support

5-Bromo-6-chloropyrazin-2-amine (Compound 110) is an organic compound used as an intermediate in the synthesis of various bioactive molecules. 5-Bromo-6-chloropyrazin-2-amine is promising for research of bacterial infections, such as tuberculosis.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

5-Bromo-6-chloropyrazin-2-amine Chemische Struktur

CAS. Nr. : 173253-42-4

Größe	Verfügbarkeit	Menge
5 g	Auf Lager	Estimated Time of Arrival: December 31
10 g	Auf Lager	Estimated Time of Arrival: December 31
25 g	Auf Lager	Estimated Time of Arrival: December 31
50 g	Auf Lager	Estimated Time of Arrival: December 31
100 g	Auf Lager	Estimated Time of Arrival: December 31
250 g	Auf Lager	Estimated Time of Arrival: December 31
500 g	Auf Lager	Estimated Time of Arrival: December 31
> 100 g	Angebot einholen

or Massenanfrage

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

This product is a controlled substance and not for sale in your territory.

Spezialitätsempfehlungen

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

Biologische Aktivität
Reinheit & Dokumentation
Verweise
Kundenbewertung

Beschreibung	5-Bromo-6-chloropyrazin-2-amine (Compound 110) is an organic compound used as an intermediate in the synthesis of various bioactive molecules. 5-Bromo-6-chloropyrazin-2-amine is promising for research of bacterial infections, such as tuberculosis^[1].
Molekulargewicht	208.44
Formel	C₄H₃BrClN₃
CAS. Nr.	173253-42-4
Appearance	Solid
Color	Light yellow to yellow
SMILES	NC1=NC(Cl)=C(Br)N=C1
Versand	Room temperature in continental US; may vary elsewhere.
Speicherung	4°C, protect from light *In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Reinheit & Dokumentation	Purity: 99.79% Select Batch: Data Sheet (266 KB) SDS (641 KB) COA (248 KB) HNMR (109 KB) RP-HPLC (283 KB) LCMS (197 KB) Handling Instructions (2659 KB)
Verweise	[1]. Szychowski J, et al. Discovery of an orally bioavailable and selective PKMYT1 inhibitor, RP-6306[J]. Journal of medicinal chemistry, 2022, 65(15): 10251-10284.